Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid; Hope S. Rugo; Sylvia Adams; Andreas Schneeweiß; Carlos H. Barrios; Hiroji Iwata; Véronique Dièras; Volkmar Henschel; Luciana Molinero; Jane Yuet Ching Hui; Vidya Maiya; Amreen Husain; Eric P. Winer; Sherene Loi; Leisha A. Emens

doi:10.1016/s1470-2045(19)30689-8

Keywords

AtezolizumabMedicineTriple-negative breast cancerOncologyInternal medicinePlaceboPaclitaxelMetastatic breast cancerDouble blindNab-paclitaxelBreast cancerChemotherapyPembrolizumabCancerImmunotherapyPathology

Affiliated Institutions

Related Publications

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés , David W. Cescon , Hope S. Rugo +97 more

Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the add...

2020 The Lancet 1658 citations

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid , Sylvia Adams , Hope S. Rugo +15 more

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...

2018 New England Journal of Medicine 4116 citations

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid , Javier Cortés , Lajos Pusztai +18 more

Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plu...

2020 New England Journal of Medicine 2718 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Aditya Bardia , Sara A. Hurvitz , Sara M. Tolaney +27 more

Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative bre...

2021 New England Journal of Medicine 1301 citations

Publication Info

Year: 2019
Type: article
Volume: 21
Issue: 1
Pages: 44-59
Citations: 1134
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1134

OpenAlex

Cite This

APA Style

                            
                                
                                    Peter Schmid, 
                                
                                    Hope S. Rugo, 
                                
                                    Sylvia Adams
                                
                                et al.
                            
                            (2019). 
                            Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. 
                            The Lancet Oncology
                            , 21
                            (1)
                            , 44-59.
                            https://doi.org/10.1016/s1470-2045(19)30689-8
                        

Identifiers

DOI: 10.1016/s1470-2045(19)30689-8